US faces infrastructure gap for psychedelic therapies

Psychedelic treatments are drawing renewed attention as potential options for depression, PTSD and other conditions, particularly for patients who have not benefited from standard care; supervised ketamine is already used clinically, while other drugs remain under study or regulatory review. Clinicians and health-system leaders say promising results alone will not ensure access: safe adoption will also require trained care teams, medical monitoring, therapeutic support, clear evidence and outcome measures, and systems for delivering treatment. Pharmacists may also help integrate any approved medicines safely into routine care. Advocates and industry representatives see a substantial unmet need and growing research momentum, but emphasize that practical infrastructure and careful implementation must accompany regulatory progress.